UK markets closed

Bone Biologics Corporation (BBLG)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4700+0.0400 (+1.65%)
At close: 04:00PM EST
2.4950 +0.02 (+1.01%)
After hours: 05:54PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.27M
Enterprise value -1.76M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.44
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.19

Trading information

Stock price history

Beta (5Y monthly) 0.59
52-week change 3-96.63%
S&P500 52-week change 326.89%
52-week high 386.8800
52-week low 32.2000
50-day moving average 33.7139
200-day moving average 39.7559

Share statistics

Avg vol (3-month) 3269.35k
Avg vol (10-day) 3241.33k
Shares outstanding 5534.24k
Implied shares outstanding 6546.61k
Float 8486.25k
% held by insiders 15.98%
% held by institutions 12.08%
Shares short (15 Feb 2024) 417.21k
Short ratio (15 Feb 2024) 40.32
Short % of float (15 Feb 2024) 43.43%
Short % of shares outstanding (15 Feb 2024) 43.22%
Shares short (prior month 12 Jan 2024) 442.32k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 324 Jul 2018
Ex-dividend date 4N/A
Last split factor 21:8
Last split date 320 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-96.34%
Return on equity (ttm)-202.15%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-8.95M
Diluted EPS (ttm)-34.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.03M
Total cash per share (mrq)5.66
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.50
Book value per share (mrq)5.44

Cash flow statement

Operating cash flow (ttm)-9.56M
Levered free cash flow (ttm)-7.21M